: Dronedarone significantly reduced the primary composite endpoint of first cardiovascular hospitalization or death by 24% compared to a placebo.

One tablet should be taken with the and one with the evening meal to ensure proper absorption. Target Population :

: Classified as Category X ; it may cause fetal harm and should not be used by pregnant women. Drug Interactions :

: The trial established dronedarone as a rhythm-control therapy specifically aimed at reducing clinical complications rather than just maintaining sinus rhythm. 2. Dronedarone (Multaq) Usage Guide

: Monitor serum creatinine levels; small increases are common but should be assessed if they persist.